OIG advisory opinion provides that payments for travel, lodging, and other costs related to a drug infusion treatment should not violate the federal Anti-Kickback Statute
In today’s video, we discuss how corporate practice of medicine fears still shape healthcare startup decisions about how to structure their digital health business, and we talk about the MSO [...]
A pharmaceutical company sought an advisory opinion to determine if payment for travel, lodging, and other costs are an inducement that violates the federal Anti-Kickback Statute.
Regulatory compliance and business transactional review of digital health companies and practices including telemedicine, medical software, health hardware, and the IoT.
FDA sends out another warning letter to CBD companies that promote that company products for medical uses and for treating diseases will be in violation of the FD&A Act.